Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Role for rexinoids is expanding
Waikoloa, Hawaii - Rexinoids such as bexarotene have promise as an adjunct to other immune response modifiers in the treatment of patients with progressive cutaneous T-cell lymphoma (CTCL), according to Jacqueline M. Junkins-Hopkins, M.D. Such therapies are typically used in combination with interferon-alpha as well as with psoralen ultraviolet-A (PUVA) and extracorporeal photopheresis (ECP).
Related Videos
Related Content
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
October 1st 2023
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
October 1st 2023
